Xilio Therapeutics (XLO) Return on Assets Growth (3y) (2024 - 2026)

Xilio Therapeutics (XLO) Return on Assets Growth (3y) (2024 - 2026) Analysis & Trends

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	65,839.48 Bn	65,839.20 Bn	-
2	Nanobiotix	1,914.07 Bn	1,914.01 Bn	-
3	Akari Therapeutics	1,009.43 Bn	1,009.43 Bn	-
4	BeOne Medicines	469.68 Bn	464.89 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.76 Bn	115.51 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.40 Bn	61.65 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.88 Bn	50.69 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.53 Bn	34.52 Bn	959.66 Mn
10	Xilio Therapeutics	145.98 Mn	-4.32 Mn	-

Download Data